Omega-3

Tier-BPublic-ready7/3/2026

Blood-Level or Deficiency Marker is closer to a research marker, so it should be read separately from a directly felt benefit.

The 61.4 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed

Caution signal

Low

Context-specific research signal

61.4

Blood-Level or Deficiency MarkerCholesterol and triglyceridesPain, headache, and migraine

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Nutrient status and deficiency

4 studiesTier-B

Blood-Level or Deficiency Marker

Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.

Evidence score

54.6

Study context

Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids

2 studiesTier-C

Cholesterol and triglycerides

Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score

48.7

Study context

Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Pain and headache

1 studiesTier-C

Pain, headache, and migraine

Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Pain and headache. These findings come from a defined study population, so everyday effects may differ.

Evidence score

44.0

Study context

Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Bone and joint health

1 studiesTier-C

Bone, joint, and mobility

Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Bone and joint health. These findings come from a defined study population, so everyday effects may differ.

Evidence score

44.0

Study context

Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Stress and mood

1 studiesTier-C

Stress Response and Sleep Changes

Some positive signal observedFelt benefit focusPatient-group study

These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.

Evidence score

44.0

Study context

Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Women's health

1 studiesTier-C

Menstrual and women's health

Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.

Evidence score

44.0

Study context

Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Observed range in repeated studies

This range includes studies in specific patient groups. It is not a general dose or recommendation.

Lower observed study value

200

mg/day

14 independent studies

Higher observed study value

1800

mg/day

Only ranges repeated in human, oral, single-ingredient studies are shown.

Not personal dosing instructions, recommendations, or safety limits.

Side effects and combination findings in studies

Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.

Caution index

0.6

Caution band: Low

Caution signals

Side effects + combos + curated rules

Key precautions

No combination caution signal is clear enough to show right now. This does not guarantee safety.

2 combo signals and 0 added-signal combos shown below.

These are signals reported in studies. They do not predict what will happen to an individual.

Positive combinations studied

Positive combination findings are separated by how the study compared the groups. This is not a recommendation to combine them.

Positive findings when used together

The combination had a positive result, but the contribution of each ingredient could not be separated.

비타민 DCombined vitamin D and omega-3 fatty acids showed a 31% reduction in autoimmune disease incidence compared to placebo, suggesting a potential additive effect.

알파리포산The combination of omega-3 fatty acids and alpha-lipoic acid showed significant benefits in slowing cognitive and functional decline compared to placebo or omega-3 alone.

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1

Public scholarly dataCitation signal: 1266

observational

[Abstract]: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are n-3 fatty acids found in oily fish and fish oil supplements. These fatty acids are able to inhibit partly a number of aspects of inflammation including leucocyte chemotaxis, adhesion mo

Key Evidence #2

Public scholarly dataCitation signal: 1111

review

[Abstract]: Inappropriate, excessive or uncontrolled inflammation contributes to a range of human diseases. Inflammation involves a multitude of cell types, chemical mediators and interactions. The present article will describe nutritional and metabolic aspect

Key Evidence #3

Public scholarly dataCitation signal: 777

observational

Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events.

3 more summariesLimited representative sample by study type.

Public scholarly dataCitation signal: 524

observational

The ongoing VITamin D and OmegA-3 TriaL (VITAL) is a large randomized, double-blind, placebo-controlled, 2×2 factorial trial of vitamin D and marine omega-3 fatty acids in the primary prevention of cancer and CVD among a multi-ethnic population of 20,000 U.S.

Public scholarly dataCitation signal: 509

review

All the new sources have potentially important roles to play in increasing the supply of n-3 LC-PUFA so that they are available more widely and in higher concentrations providing more options and opportunities for human consumers to obtain sufficient EPA and D

Public scholarly dataCitation signal: 345

rct

[Abstract]: There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders. We conducted a randomized, double-blind, placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of

Omega-3

Evidence score: 61.4|Caution index: 0.6

arrow_backBack to list